NOI - A Non-Invasive Prognostic Biomarker

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98027Q00001

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

AN11

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents1
The National Institutes of Health (NIH), Office of the Director, Office of Acquisitions, has issued a combined synopsis/solicitation (Procurement Identifier: 75N98027Q00001) for the procurement of research support services focused on the development and validation of a non-invasive prognostic biomarker. Specifically, this effort seeks to advance circulating cell-free DNA (cfDNA) as a blood-based biomarker for chlorine-induced acute lung injury. The intended outcome is to establish a reliable, non-invasive diagnostic tool that can be used to assess and predict the severity of lung injury resulting from chlorine exposure, thereby supporting both clinical and research applications in pulmonary medicine. This procurement is being conducted as a Notice of Intent (NOI) to award a firm-fixed-price purchase order on a non-competitive basis. The NIH intends to negotiate exclusively with the University of Alabama at Birmingham, located at 701 S 20th Street, Birmingham, AL 35294-0001-0001. The rationale for this sole-source award is based on the unique capabilities of the Matalon Laboratory at this institution, which include a validated murine chlorine inhalation injury model, specialized mechanistic expertise, access to an actively enrolling aspiration pneumonitis biorepository (serving as a human proxy cohort), established collaborative infrastructure with the NHLBI Laboratory of Precision Omics, and ongoing peer-reviewed federal funding (NIH R01 HL031197). These resources and expertise are deemed essential to the feasibility and success of the project and are not available from any other source. The scope of work encompasses research and development activities in biotechnology, with a focus on translational and precision medicine approaches. The contractor is expected to leverage existing animal models, human biorepository samples, and collaborative networks to validate cfDNA as a prognostic biomarker. Key deliverables will likely include validated assay protocols, data supporting the biomarker’s predictive value, and integration with ongoing NIH research initiatives. This opportunity falls under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology), with a small business size standard of 1,000 employees. However, this requirement is not set aside for small business participation. The procurement is governed by Federal Acquisition Regulation (FAR) Subpart 12.6 and is being executed under the streamlined procedures for commercial products or services, as authorized by FAR 12.603 and 41 U.S.C. 1901. The applicable Federal Acquisition Circular is 2026-01, effective as of March 13, 2026. The contracting entity for this procurement is the NIH Office of Logistics and Acquisition Operations (OLAO), a federal office within the Department of Health and Human Services. The primary point of contact for this notice is Nicholas S. Capobianco, who can be reached via email at [email protected]. Interested parties should note that this is a non-competitive action and proposals are being solicited only from the identified source. The notice was posted on October 13, 2026, with a response deadline of October 23, 2026. The opportunity is currently listed as inactive. Additional details and any attachments related to this notice can be accessed via the SAM.gov opportunity ID d444ba3064714987a61e08e7c6cfb7c1. Contractors considering this opportunity should recognize that the requirements are highly specialized and tailored to the unique capabilities of the University of Alabama at Birmingham’s Matalon Laboratory. The project’s success depends on access to proprietary models, biorepositories, and established research collaborations, which are not broadly available in the marketplace.